RADNOR, PA — Avantor, Inc. (NYSE: AVTR) said it has appointed Simon Dingemans to its Board of Directors, effective January 2, 2026, adding a seasoned global executive as the life sciences supplier presses ahead with efforts to revive growth and sharpen profitability.
Dingemans brings decades of experience across healthcare, finance, and large-scale corporate transformation. He previously served as chief financial officer of GlaxoSmithKline plc and held senior roles at Goldman Sachs and The Carlyle Group. He currently sits on the boards of Vodafone Group Plc and WPP plc.
Gregory Summe, the incoming chairman of Avantor’s board, said the appointment aligns with the company’s push to accelerate performance under its so-called Avantor Revival plan. He described Dingemans as a leader with deep experience in financial discipline, operational improvement, and strategic execution across complex global organizations.
Avantor has faced pressure from investors to improve margins and execution following uneven performance in recent quarters, as demand across parts of the life sciences sector normalized after pandemic-era surges. The company supplies mission-critical materials and services to customers in biopharma, healthcare, education, and advanced technologies.
Dingemans said Avantor’s portfolio of products and services has positioned it as a trusted partner to the scientific community worldwide. He said he looks forward to supporting efforts to drive operational improvements, strengthen customer relationships, and position the company for sustainable long-term performance.
During his tenure at GlaxoSmithKline, Dingemans oversaw major technology and business services modernization initiatives, guided capital allocation, and supported strategic transactions that reshaped the company’s portfolio. Earlier in his career, he led UK investment banking and European mergers activity at Goldman Sachs International and later held senior advisory and operating roles at The Carlyle Group.
He holds bachelor’s and master’s degrees in geography from the University of Oxford and also serves as a board member of Genomics LTD, where he is non-executive chair.
The board appointment comes as Avantor seeks to stabilize operations and reassure investors that experienced leadership is in place to navigate a more demanding market environment.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.